BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
US Department of Justice
Cantor Fitzgerald

Generated: September 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method of treating pulmonary hypertension with benzidine prostaglandins
Abstract:The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --; R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, or R is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; and the dotted line represents an optional double bond; or of a physiologically acceptable salt or acid derivative thereof. Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
Inventor(s): Tadepalli; Anjaneyulu S. (Durham, NC), Long; Walker A. (Chapel Hill, NC), Crow; James W. (Raleigh, NC), Klein; Kenneth B. (Chapel Hill, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/715,439
Patent Claims: 1. A method of treating pulmonary hypertension in a patient, which comprises administering to said patient an effective pulmonary hypertension treatment amount of the compound 9-deoxy-2',9.alpha.-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)- 13,14-dihydro-prostaglandin F.sub.1.

2. A method of treating pulmonary hypertension in a patient, which comprises administering to said patient an effective pulmonary hypertension treatment amount of a pharmaceutically acceptable salt of the compound 9-deoxy-2',9.alpha.-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)- 13,14-dihydroprostaglandin F.sub.1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Queensland Health
Daiichi Sankyo
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus